Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trialGıancarlo Comı, Jeffrey A. Cohen, Douglas L. Arnold et al.|The Lancet Neurology|2019Cited by 286
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialJeffrey A. Cohen, Ludwig Kappos, Gıancarlo Comı et al.|The Lancet Neurology|2019Cited by 279